> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-99/
- Published: 2017-07-23T12:00:00.000Z
- Updated: 2026-09-14T22:35:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139199

**Mitsubishi Tanabe Pharma** has agreed to acquire **NeuroDerm**, a clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders. Mitsubishi will pay $39 per share in cash, which is 79% above currently traded shares.

**Emergent BioSolutions** has agreed to acquire a drug used to treat anthrax from **GlaxoSmithKline** in a deal worth up to $96 million. Under the agreement, Emergent will pay $76 million cash upfront and up to $20 million in product sales and milestone payments to acquire raxibacumab.

**Gurnet Point**, a healthcare investment fund, has completed its acquisition of **Innocoll Holdings**, a global pharmaceutical and medical device company, for an estimated $209 million. Gurnet Point is also providing a $10 million term loan to provide additional resources needed for the continued development of Xaracoll, Innocoll’s late-stage surgically implantable and bioresorbable collagen matrix.